Physician profile
Leo Jeng
NPI 1821275959
$50,944.67
in general payments reported to CMS, 2019-2025
43 companies · $1,618 in 2025
The $1,618 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $10K · 2021: $5,745 · 2022: $1,284 · 2023: $931 · 2024: $1,812 · 2025: $1,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644 · Consulting Fee: $1,050 · Travel and Lodging: $655 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.48 |
| Consulting Fee | $1,050.00 |
| Travel and Lodging | $655.47 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36,967.49 | 2019-2023 | Wegovy |
| Sanofi-Aventis U.S. LLC | $3,413.33 | 2019-2025 | |
| Lilly USA, LLC | $1,863.78 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Tandem Diabetes Care, INC. | $1,778.27 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $1,078.41 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Mannkind Corporation | $1,034.66 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals Lp | $1,015.13 | 2019-2021 | |
| Insulet Corporation | $870.43 | 2019-2024 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.97 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $299.73 | 2020-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $265.54 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $219.30 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $215.94 | 2019-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $167.38 | 2019-2021 | |
| Zealand Pharma US, INC. | $165.53 | 2020-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Jeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.